Literature DB >> 10514461

Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa.

P J Fay1, D Scandella.   

Abstract

Factor VIIIa, a heterotrimer of the A1, A2, and A3-C1-C2 subunits, increases the catalytic efficiency for factor IXa-catalyzed activation of factor X. A significant fraction of naturally occurring, anti-factor VIII inhibitor antibodies reacts with the A2 domain. Utilizing the capacity for isolated A2 subunit to stimulate factor IXa activity, we show that a panel of these inhibitors block this activity. Inhibition of activity parallels the antibody potency as measured in the Bethesda assay. These antibodies also block the A2-dependent increases in fluorescence anisotropy of fluorescein-Phe-Phe-Arg factor IXa. Similar to the IgG fractions, a peptide representing the sequence of the inhibitor epitope (A2 residues 484-509) blocked the A2-dependent stimulation of factor IXa. These results indicate that antibodies possessing this specificity directly inhibit the interaction of A2 subunit with factor IXa, thus abrogating the contribution of this subunit to cofactor activity. Furthermore, these results also suggest that factor VIII residues 484-509 contribute to a factor IXa-interactive site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514461     DOI: 10.1074/jbc.274.42.29826

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 2.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

3.  Inhibitory antibodies against factor VIII C1 domain.

Authors:  Gary E Gilbert
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

4.  Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction.

Authors:  A E Griffiths; W Wang; F K Hagen; P J Fay
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

5.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Authors:  Leonard Moise; Chang Song; William D Martin; Ryan Tassone; Anne S De Groot; David W Scott
Journal:  Clin Immunol       Date:  2011-12-08       Impact factor: 3.969

6.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

Review 7.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 8.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

9.  High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Authors:  Phuong-Cac T Nguyen; Kenneth B Lewis; Ruth A Ettinger; Jason T Schuman; Jasper C Lin; John F Healey; Shannon L Meeks; Pete Lollar; Kathleen P Pratt
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

10.  Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.

Authors:  Karthik Ramani; Vivek Purohit; Razvan Miclea; Puneet Gaitonde; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.